ArticlePharmaceutical research2026
Cholesterol-Based Lipid Nanoparticles as an Intracellular Drug Reservoir for Enhanced Tumor Therapy.
Article in Pharmaceutical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveCancer remains a critical public health challenge. Conventional anti-tumor drugs are often limited by their short half-life and the requirement for frequent and/or high-dose administration, highlighting the urgent need for drug delivery systems that can enhance intracellular drug accumulation.
methodsGiven that current research on drug delivery systems primarily focuses on developing active or passive targeting strategies to improve therapeutic efficacy, biocompatible cholesterol-based lipid nanoparticles (Cls-LNPs) were developed in this study. The Cls-LNPs were designed to function as an "intracellular drug reservoir" by enhancing cellular uptake and retention, thereby meeting the core requirement of enhanced intracellular drug accumulation.
resultsThe reservoir capacity is likely attributed to the ability of Cls-LNPs to evade lysosomal degradation and target the endoplasmic reticulum (ER). When combined with the emerging anti-tumor technology of photodynamic therapy (PDT) and utilizing Ce6 as a model photosensitizer, the prepared Ce6@Cls-LNPs exhibited enhanced anti-tumor efficacy both in vitro and in vivo compared to free drugs. The therapeutic effect was achieved through the induction of ER stress, lipid peroxidation, and apoptosis, and it also exhibited a "bystander effect".
conclusionThis study offers valuable insights into the application of cholesterol in drug delivery systems and proposes innovative strategies for the development of retention-enhancing formulations.
Indexed as
Identifiers
41721070What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.